4. "Full Market Awareness" A professional relations company and consulting firm Contact: Sean McDonald smcdonald@acornmanagementpartners.com 941 . 208.3919 Atlanta,Georgia & Sarasota,Florida Disclaimer Notice: The information contained in this e-mail message and its attachments is intended solely for the use of the individual(s) to whom it is addressed and may contain information that is the confidential information of Acorn Management Partners L.L.C. ("AMP") and its subsidiaries. The Information may be about companies in which A.M.P has or may receive compensation in the future. Any material in this message should be considered as ADVERTISEMENT ONLY. Please consult with a certified financial advisor before making any investment decisions. All information on this report should be confirmed before making an investment decision. Acorn Management Partners L.L.C. ("AMP") and its subsidiaries, and any affiliates and information providers make no implied or express warranties on the information provided. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies involve a high degree of risk and volatility, and all investors/advisors should know that they may lose a portion or all of their investment if they decide to purchase any stock. Acorn Management Partners L.L.C. ("AMP"), its affiliates, associates, relatives and anyone associated with in any manner reserves the right to either buy or sell shares in the profiled company's stock. The Securities and Exchange Commission has compiled an extensive amount of information concerning investing, including the inherent risks involved. We encourage our readers to visit the SEC's website to acquire this important information. Safe Harbor Disclosure: Acorn Management Partners L.L.C. ("AMP") website publications may contain or incorporate by reference "forward- looking statements, including certain information with respect to plans and strategies of the featured company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the forgoing, the words "believe(s)," "anticipate(s)," "plan(s)," "expect(s)," "project(s)" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the Companies profiled herein to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends, future operating revenues and expenses. Although the Company believes that the statements are reasonable, it can give no assurances that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company or contained in any and/or all profile/ research reports, contain no guarantee of future performance, and that the actual result may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various fa ctors including, but not limited to, the Company's ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. Any statements that express or involve discussions with respect to predictions, expectat ions, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking stat ements in this action may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," "may," or by statements indicating certain actions "may," "could," or "might" occur. We encourage our readers to invest carefully and review all forms of investments and read the investor information. More information please visit http:// www.sec.gov and/or (FINRA) at: http://www.FINRA.com. Readers can review all public filings by compan ies at the SEC's EDGAR page. The FINRA has published information on how to invest carefully at its websi te.

2. Continue Reading for Recent News, Management Background and Our Disclosure... Preclinical Stage Platforms: SCAs and a7nAChR SCAs Platform: Synthetic CBD Analogs for Pain & Inflammation Led by Prof. Sir Marc Feldmann; key players include Mechoulam, Domb • A real alternative to unregulated consumption of medical cannabis or OTC CBD (no clinical evidence, not FDA approved, unreliable composition, unpredictable dosing and safety) • Safe & non-psychoactive • Formulated to offer improved oral bio-availability (>3x) • Rigorously tested in clinical trials for inflammatory pain (efficacy and dosing) • Granted market approval by FDA, EMA and others *180 LS Corporate Presentation a7nAChR Platform: Novel Platform for Ulcerative Colitis Led by Dr. Jonathan Rothbard and Prof. Larry Steinman • a7nAChR is a nicotine acetylcholine receptor and a central factor in evolutionarily ancient neural circuit to control of inflammation(1,2) • Large pharma initially touted a7 as a pharmaceutical target for Alzheimer’s disease and schizophrenia o Multiple specific agonists developed o All shown to be safe, but did not meet milestones in human clinical trials • 180 Life Sciences aims to re-purpose a7nAChR for inflammation o Nicotine binds a7 and is a known immune suppressive o A subgroup of patients who cease smoking subsequently acquire ulcerative colitis (a large, growing market: 2012 - $4.2B; 2022 - $6.6B) o Treatment has a high probability of therapeutic success (can be viewed as nicotine replacement therapy without issues of addiction) IP Portfolio: Overview 180 Life Sciences Pipeline:

3. Continue Reading for Our Disclosure... Pioneering Founders Prof. Sir Marc Feldmann University of Oxford Executive Co-Chairman • Pioneer of anti-TNF therapy, world’s biggest drug class ($40B/yr) • Anti-TNF discovery of Remicade eventually led to Centocor’s acquisition by J&J for $4.9B • International awards for biomedical innovations: Crafoord, Lasker, Canada Gairdner, Janssen, EU Inventor of the Year, Tang • UK and Australian knighthood • Fellow of Royal Society and Australian Academy of Science; member of National Academy of Sciences Prof. Lawrence Steinman Stanford University Executive Co-Chairman • Discovered role of integrins, which led to natalizumab (Tysabri, sold to Biogen for$3.25B), a highly effective treatment for MS and IBD • Founder of Neurocrine Biosciences • Board member of Centocor, sold to J&J for $4.9B • International awards for biomedical innovations: Sasse, Dystel, Charcot, Cerami, Javits (twice) • Member of National Academy of Medicine and National Academy of Sciences Prof. Raphael Mechoulam Hebrew University Co-Founder • Father of cannabis research; isolated numerous cannabinoids, including delta9-THC • Discovered endogenous cannabinoids 2AG and anandamide • Published over 400 papers in esteemed scientific journals • International awards for biomedical innovations: Israeli Prize in Exact Sciences, NIDA Discovery, Rothschild, Lifetime Achievement at CannaMed • Member of Israel Academy of Sciences and Humanities Prof. Jagdeep Nanchahal University of Oxford Co-Founder; Chair, Clinical Advisory Board • Pioneered the treatment of fibrosis of the hand (Dupuytren’s disease) by identifying TNF as a target • Surgeon-scientist, leading Phase 2b/3 trial for Dupuytren’s disease funded by Wellcome Trust and UK Dept. of Health • Fellow of the Royal College of Plastic Surgeons Recent News: • 180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit • 180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering • 180 Life Sciences Corp. Issues Letter to Stockholders • 180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease • 180 Life Sciences Corp. Issues Letter to Stockholders • 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology • 180 Life Sciences Corp. Forms Scientific Advisory Board • 180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases • 180 Life Sciences Corp. Expands Patent Portfolio

1. AMP Quick Facts 180 Life Sciences Corp. (NasdaqCM: ATNF ) Acorn Management Partners, LLC August 2022 Nasdaq: ATNF Price: $ 1 . 26 Date: 0 8 / 0 4 /20 22 Fiscal Year: 12/31 MKT Cap: ~ $ 47 . 4 m C.O.H*: ~ $ 5.67 m Inside Ownership: ~ 35 . 3 3 % S/O*: ~ 3 7 . 6 4 m Float: ~ 23. 3 2 m AVG Vol.: ~ 292.4 k For More Information Please Email: Brandon Bouysou brandon@acornmanagement partners.com Industry: Healthcare Biotechnology * As of most recent filing Continue Reading for More Information, Recent News, Management Background & Our Disclosure... 180 Life Sciences (ATNF) is developing new treatments for one of the world's biggest drivers of disease: inflammation. The programs are led by world-leading scientists at prestigious universities who have already developed blockbuster drugs and made ground-breaking discoveries in their fields. Clinical Stage Program s : Led by Profs. Jagdee p Nanchahal a nd Sir Marc Feldmann, Oxford The company is a clinical stage biotechnology company headquartered in Palo Alto, California, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. 180 Life Sciences has three different product development families that are focused on different diseases or medical conditions, and that target different factors, molecules or proteins, as follows: Anti-TNF (focusing on fibrosis and anti-tumor necrosis factor), SCAs (focusing on drugs which are synthetic cannabidiol or cannabigerol analogs), and α7nAChR (focusing on alpha 7 nicotinic acetylcholine receptor). The company was founded by Prof. Sir Marc Feldmann (Oxford), Prof. Lawrence Steinman (Stanford), Prof. Raphael Mechoulam (Hebrew University), Dr. Jonathan Rothbard (Stanford) and Prof. Jagdeep Nanchahal (Oxford), all of whom are scientists in the biotechnology and pharmaceutical sectors with significant experience and demonstrated success in drug discovery. The company is led by a management team with decades of extensive operational, financing and early-stage healthcare company experience Institutional Ownership: ~ 8.14 % Investment Highlights: